2d
Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids
Rocket Pharmaceuticals (NASDAQ:RCKT) said the U.S. Food and Drug Administration has granted accelerated approval to KRESLADI ...
VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in ...
These findings strengthen the evidence that microbiome composition plays a substantive role in sulforaphane formation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results